期刊简介
本杂志是由中华人民共和国卫生部主管，同济医科大学附属协和医院主办，国内外公开发行的学术性期刊，被国家科技部列为“中国科技论文统计源期刊”，被中国科学文献计量评价研究中心认定为《中国科学引文数据库》来源期刊。设有专家笔谈、临床研究、实验研究、研究报告、综述、进修苑、学术争鸣、经验介绍及病例报告等栏目。
往期目录
-
1999
-
2000
-
2001
-
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
首页>临床血液学杂志
- 杂志名称：临床血液学杂志
- 主管单位：中华人民共和国教育部
- 主办单位：华中科技大学同济医学院附属协和医院 北京大学医学院血研所
- 国际刊号：1004-2806
- 国内刊号：42-1284/R
- 出版周期：双月刊
期刊荣誉：中国核心期刊数据库收录期刊期刊收录：国家图书馆馆藏, 万方收录(中), 上海图书馆馆藏, CA 化学文摘(美), 统计源核心期刊(中国科技论文核心期刊), 知网收录(中), 维普收录(中)
阿糖胞苷治疗急性髓系白血病的耐药机制研究进展
任雨虹；李军民
关键词：阿糖胞苷, 白血病, 髓系, 急性, 耐药
摘要：Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy characterized by the proliferation and infiltration of poorly differentiated hematopoietic cells in the bone marrow,blood and tissues.Cytarabine is a kind of nucleoside analogues mostly used in the induction and consolidation therapy of AML.High dose cytarabine proved to be more effective in killing leukemic cells while it also brought more adverse effect and resistance.Based on its metabolic pathways in vivo,researchers found that insufficient uptake of cytarabine into cells,decrease of activating enzymes and activated products,increase of inactivating enzymes and intracellular dCTP amount could be the cause of cytarabine resistance in AML.Further investigation on the potential enzymes and candidate genes has been carried out in order to improve complete remission rates,overall survival and disease free survival of AML.This article will review recent advances in the mechanism of resistance to cytarabine therapy in AML.
友情链接